On The Sunny Side Of Trump Street: Biopharma Ready For Tax Reform
Industry experts expressed optimism for tax reform at the Biotech Showcase and J.P. Morgan Healthcare Conference, though there is concern about the future of the federal Small Business Innovation Research program.
You may also be interested in...
Beyond pricing, industry experts weigh in on how the next administration has shifted expectations across a range of areas – including tax reform, FDA standards and the Cancer Moonshot Initiative.
To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.
US biopharmas are holding billions in cash overseas to avoid paying America’s high corporate tax rate, so the prospect of a US tax holiday – or broad tax reform – will be welcomed by industry.